BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

Abstract excerpt

// G.S. Falchook 1 , J.C. Trent 2 , M.C. Heinrich 3 , C. Beadling 3 , J. Patterson 3 , C.C. Bastida 1 , S.C. Blackman 4 , R. Kurzrock 5 1 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 2 Sarcoma Medical Oncology Program, University of Miami, Sylvester Comprehensive Cancer Center,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colorectal Cancer Treatments and Studies
• Share to Gastric Cancer Management and Outcomes
• Share to Gastrointestinal Tumor Research and Treatment